Table 1.
Demographic data for participants receiving Pfizer/BNT162b2 initial vaccine series and booster
| N (%) | |
|---|---|
| Sex | |
| Female | 25 (64.1) |
| Male | 14 (35.9) |
| Race | |
| White | 26 (66.6%) |
| Asian | 8 (20.5%) |
| Black | 4 (10.3%) |
| Multiracial | 1 (2.6%) |
| Occupation | |
| Nurse | 11 (28.2%) |
| Physician | 11 (28.2%) |
| Physical/Occupational/Recreational Therapist | 9 (23.1%) |
| Medical Technician | 3 (7.7%) |
| Lab Personnel | 3 (7.7%) |
| Social Worker | 1 (2.6%) |
| Psychologist | 1 (2.6%) |
| Anti-N seroconversion after vaccination and before boost | |
| Positive | 17 (43.6%) |
| Negative | 22 (56.3%) |
| Age | |
| Mean age ± SD (range) | 45 ± 11 (26 – 69) |
| Time between second vaccine and sample collection | |
| Mean days ± SD (range) | 30 ± 11 (28 – 34) |
| Time between second vaccine and booster dose | |
| Mean days ± SD (range) | 267 ± 14 (218–310) |
| Time between booster dose and sample collection | |
| Mean days +/− SD (range) | 43 ± 17 (7 – 93) |